John M Kirkwood

John M Kirkwood

UNVERIFIED PROFILE

Are you John M Kirkwood?   Register this Author

Register author
John M Kirkwood

John M Kirkwood

Publications by authors named "John M Kirkwood"

Are you John M Kirkwood?   Register this Author

100Publications

6552Reads

35Profile Views

An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.

Cancer 2019 Sep 8;125(17):3013-3024. Epub 2019 May 8.

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32162DOI Listing
September 2019

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations.

J Immunother Cancer 2019 Sep 4;7(1):239. Epub 2019 Sep 4.

First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, 11527, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0717-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727332PMC
September 2019

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade.

JAMA Oncol 2019 Jul;5(7):942-943

Division of Hematology-Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0413DOI Listing
July 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

J Immunother Cancer 2019 Apr 24;7(1):113. Epub 2019 Apr 24.

Department of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0552-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480917PMC
April 2019

PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy.

Sci Rep 2019 Mar 1;9(1):3309. Epub 2019 Mar 1.

Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-39542-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397203PMC
March 2019

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα and Gα and kill uveal melanoma cells.

Cancer Biol Ther 2019 20;20(5):700-710. Epub 2018 Dec 20.

a Departments of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2018.1551747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606002PMC
December 2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

J Clin Oncol 2018 Oct 25:JCO1800632. Epub 2018 Oct 25.

Diwakar Davar, Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, Julien J. Fourcade, Mignane Ka, Carmine Menna, Amy Rose, Cindy Sander, Amir A. Borhani, Arivarasan Karunamurthy, John M. Kirkwood, and Hassane M. Zarour, University of Pittsburgh, Pittsburgh, PA ; Ahmad A. Tarhini, Cleveland Clinic, Cleveland, OH; Hussein A. Tawbi, The University of Texas MD Anderson Cancer Center, Houston, TX; and Qing Zhao, Blanca H. Moreno, Scott Ebbinghaus, and Nageatte Ibrahim, Merck, Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00632
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286160PMC
October 2018

Management strategies of academic pigmented lesion clinic directors in the United States.

J Am Acad Dermatol 2018 Aug 4;79(2):367-369. Epub 2018 Jan 4.

Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2017.12.069DOI Listing
August 2018

Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.

Melanoma Res 2018 06;28(3):211-221

Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000441DOI Listing
June 2018

Psychosocial consequences of skin cancer screening.

Prev Med Rep 2018 Jun 17;10:310-316. Epub 2018 Apr 17.

Department of Epidemiology, Brown School of Public Health, Providence, RI, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pmedr.2018.04.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984251PMC
June 2018

Anti-PD-1 antibody treatment for melanoma.

Lancet Oncol 2018 05;19(5):e219

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30202-XDOI Listing
May 2018

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

J Immunother Cancer 2018 05 14;6(1):35. Epub 2018 May 14.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0342-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950135PMC
May 2018

Estimating the cost of skin cancer detection by dermatology providers in a large health care system.

J Am Acad Dermatol 2018 04 24;78(4):701-709.e1. Epub 2017 Nov 24.

Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2017.11.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963718PMC
April 2018

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

J Clin Oncol 2018 02 17;36(4):391-398. Epub 2017 Oct 17.

Margaret K. Callahan, Michael A. Postow, Neil H. Segal, Alexander Lesokhin, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Harriet Kluger and Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, and Yale-New Haven Hospital, New Haven, CT; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; and Suba Krishnan, Rafia Bhore, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.2850
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.2850DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946731PMC
February 2018

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

J Clin Oncol 2018 02 12;36(4):399-413. Epub 2017 Dec 12.

Sandra L. Wong, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Mark B. Faries, The Angeles Clinic and Research Institute, Santa Monica; Alistair Cochran, University of California, Los Angeles Center for Health Services, Los Angeles, CA; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; Sanjiv S. Agarwala, St Luke's Cancer Center, Easton; John M. Kirkwood, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Timothy J. Akhurst, Peter MacCallum Cancer Centre, Victoria, Australia; Charlotte Ariyan, Memorial Sloan Kettering Cancer Center, New York, NY; Charles M. Balch, MD Anderson Cancer Center, Houston, TX; Barry S. Berman, Broward Health, Fort Lauderdale; Jonathan S. Zager, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Keith A. Delman, Emory University, Atlanta, GA; Mark Gorman, Silver Spring, MD; Marc D. Moncrieff, Norfolk and Norwich University Hospital, Norwich, United Kingdom; and Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.7724DOI Listing
February 2018

Adjuvant Therapy in Resected Melanoma.

N Engl J Med 2018 02;378(7):679-680

Hillman UPMC Cancer Center, Pittsburgh, PA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1716071DOI Listing
February 2018

Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma.

J Extracell Vesicles 2018 15;7(1):1435138. Epub 2018 Feb 15.

Department of Pathology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20013078.2018.1435138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827723PMC
February 2018

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

J Natl Cancer Inst 2018 01;110(1)

European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France; The Christie NHS Foundation Trust, Manchester, UK; University of Pittsburgh Cancer Institute and School of Medicine, Pittsburgh, PA; Mayo Clinic Rochester, Rochester, MN; University of Tubingen, Tubingen, Germany; University of Edinburgh, Western General Hospital, Edinburgh, UK; Bristol-Myers Squibb, Wallingford, CT; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK; Universitas Brawijaya, Malang, Indonesia; IDDI, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx133DOI Listing
January 2018

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

J Clin Oncol 2017 Dec 15;35(34):3815-3822. Epub 2017 Sep 15.

Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Pier Francesco Ferrucci, Istituto Europeo di Oncologia, Milan; Massimo Guidoboni, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; David Hogg, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Celeste Lebbé, Université Paris Diderot, Paris; Luc Thomas, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; John M. Kirkwood, Hillman Cancer Center, Pittsburgh, PA; Jacob Schachter, Sheba Medical Center, Ramat Gan, Israel; Gregory A. Daniels, University of California San Diego, Moores Cancer Center, La Jolla, CA; Jessica Hassel, University Hospital, Heidelberg, Germany; Jonathan Cebon, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria; Winald Gerritsen, University of Queensland, St Lucia; Victoria Atkinson, Gallipoli Medical Research Foundation, Greenslopes; Victoria Atkinson, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Winald Gerritsen, Radboud University Medical Center, Nijmegen, the Netherlands; John McCaffrey, Irish Clinical Oncology Research Group, Dublin; Derek Power, Irish Clinical Oncology Research Group, Cork, Ireland; Dana Walker, Rafia Bhore, and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; and Jedd D. Wolchok, Parker Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1167DOI Listing
December 2017

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.

Melanoma Res 2017 10;27(5):429-438

aDepartment of Medicine, University of Pittsburgh School of Medicine bUniversity of Pittsburgh Cancer Institute cUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA dAthens Naval and Veterans Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657445PMC
October 2017

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.

J Immunother Cancer 2017 09 19;5(1):74. Epub 2017 Sep 19.

Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0279-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604296PMC
September 2017

Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.

JCI Insight 2017 09 21;2(18). Epub 2017 Sep 21.

Department of Pediatrics and Microbiology/Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.93265DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621898PMC
September 2017

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.

Melanoma Res 2017 08;27(4):342-350

aDepartment of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania bLudwig Institute for Cancer Research Ltd, New York, New York cDepartment of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000353DOI Listing
August 2017

Collaborative Care in Melanoma: The Essential Role of the Nurse
.

Clin J Oncol Nurs 2017 08;21(4 Suppl):4-6

University of California, Los Angeles Jonsson Comprehensive Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/17.CJON.S4.4-6DOI Listing
August 2017

Interferon-γ Drives T Fragility to Promote Anti-tumor Immunity.

Cell 2017 Jun 25;169(6):1130-1141.e11. Epub 2017 May 25.

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.05.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509332PMC
June 2017

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

J Clin Oncol 2017 Mar 30;35(8):885-892. Epub 2017 Jan 30.

Sanjiv S. Agarwala, Saint Luke's University Hospital, Easton; Uma N. Rao, Ahmad A. Tarhini, Terry L. Evans, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra J. Lee, and Waiki Yip, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD; Douglas S. Reintgen, Lakeland Regional Cancer Center, Lakeland; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL; Joanna M. Brell, MetroHealth Medical Center, Cleveland; William E. Carson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mark R. Albertini, University of Wisconsin Hospital, Madison, WI; Michael B. Atkins, Georgetown Medical Center, Washington, DC; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Robert M. Conry, University of Alabama at Birmingham, Birmingham, AL; Jeffrey A. Sosman, Vanderbilt University, Nashville; Alberto S. Pappo, Saint Jude Children's Research Hospital Oncology, Memphis, TN; Lawrence E. Flaherty, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Michael G. Smylie, Cross Cancer Institute, Edmonton, Canada; and Richard F. Kefford, Sydney West Area Health Service, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684PMC
March 2017

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.

Oncotarget 2017 Mar;8(10):16367-16386

Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.14829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369969PMC
March 2017

Downstream consequences of melanoma screening in a community practice setting: First results.

Cancer 2016 Oct 8;122(20):3152-3156. Epub 2016 Jul 8.

Melanoma and Skin Cancer Program, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286549PMC
October 2016

BRAF Inhibitors and IFNα: Plus, Minus, or Indeterminate?

J Natl Cancer Inst 2016 Jul 5;108(7). Epub 2016 Feb 5.

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA (DD, JMK); Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, PA (SYF).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv432DOI Listing
July 2016

IFN-λ cancer immunotherapy: new kid on the block.

Immunotherapy 2016 07;8(8):877-88

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, PA, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2015-0021
Publisher Site
http://dx.doi.org/10.2217/imt-2015-0021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619162PMC
July 2016

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Int J Radiat Oncol Biol Phys 2016 06;95(2):632-46

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://ocpe.mcw.edu/sites/ocpe.mcw.edu/files/users/561/Avoid
Web Search
http://dx.doi.org/10.1016/j.ijrobp.2016.01.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102246PMC
June 2016

Neoadjuvant treatment for melanoma: current challenges and future perspectives.

Melanoma Manag 2016 Jun 25;3(2):149-159. Epub 2016 May 25.

Medicine, Dermatology & Translational Science, University of Pittsburgh School of Medicine, Melanoma & Skin Cancer Program, UPCI, Hillman Cancer Center, 5115 Centre Avenue, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2015-0001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094612PMC
June 2016

A pragmatic approach to melanoma screening in collaboration with primary care providers.

Cutis 2016 Jun;97(6):382-3

Department of Dermatology, School of Medicine, University of Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
June 2016

Association of TERT promoter mutations with telomerase expression in melanoma.

Pigment Cell Melanoma Res 2016 May;29(3):391-3

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248652PMC
May 2016

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

Clin Cancer Res 2016 Jan 25;22(2):374-82. Epub 2015 Aug 25.

Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821426PMC
January 2016

Adjuvant Therapy of Melanoma.

Cancer Treat Res 2016 ;167:181-208

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-22539-5_7
Publisher Site
http://dx.doi.org/10.1007/978-3-319-22539-5_7DOI Listing
January 2016

Tenascin-C Signaling in melanoma.

Cell Adh Migr 2015 ;9(1-2):125-30

a Department of Pathology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/19336918.2014.972781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422811PMC
December 2015

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).

J Clin Oncol 2015 Dec 8;33(34):4066-76. Epub 2015 Sep 8.

David H. Lawson, Winship Cancer Institute of Emory University, Atlanta, GA; Sandra Lee and Fengmin Zhao, Dana-Farber Cancer Institute; Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA; Ahmad A. Tarhini, Theresa L. Whiteside, Lisa H. Butterfield, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Kim A. Margolin, Seattle Cancer Care Alliance, Seattle, WA; Marc S. Ernstoff, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.0500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669592PMC
December 2015

CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux.

Clin Cancer Res 2015 Dec;21(24):5412-4

Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683414PMC
December 2015

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.

Case Rep Oncol Med 2015 10;2015:737389. Epub 2015 Sep 10.

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/737389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581502PMC
October 2015

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.

J Immunother Cancer 2015 15;3:39. Epub 2015 Sep 15.

University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue (555), Pittsburgh, PA 15232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0081-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570556PMC
September 2015

Immune checkpoint blockade and interferon-α in melanoma.

Semin Oncol 2015 Jun 14;42(3):436-47. Epub 2015 Feb 14.

University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Cancer Institute, Pittsburgh, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.02.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429252PMC
June 2015

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Cancer Res 2015 Apr 26;75(8):1635-44. Epub 2015 Feb 26.

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401638PMC
April 2015

Unfolding the mutational landscape of human melanoma.

J Invest Dermatol 2015 Mar;135(3):659-662

Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X153716
Publisher Site
http://dx.doi.org/10.1038/jid.2014.467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466551PMC
March 2015

Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement.

JAMA Dermatol 2015 Feb;151(2):212-8

Melanoma and Pigmented Lesion Clinic, Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia15Division of Dermatology, Atlanta Veterans Administration Medical Center, Decatur, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2014.2694DOI Listing
February 2015

Classification of current anticancer immunotherapies.

Oncotarget 2014 Dec;5(24):12472-508

Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.

View Article

Download full-text PDF

Source
https://lirias.kuleuven.be/bitstream/123456789/502976/1/2998
Web Search
http://oncotarget.com/abstract/2998
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350348PMC
http://dx.doi.org/10.18632/oncotarget.2998DOI Listing
December 2014

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

J Clin Oncol 2014 Nov 20;32(33):3771-8. Epub 2014 Oct 20.

Lawrence E. Flaherty, Wayne State University, Detroit; Bruce G. Redman, University of Michigan, Ann Arbor, MI; Megan Othus, James Moon, Southwest Oncology Group Statistical Center; John A. Thompson, Seattle Cancer Care Alliance, Seattle, WA; Michael B. Atkins, Georgetown University Hospital, Washington DC; Ralph J. Tuthill, Cleveland Clinic Foundation, Cleveland, OH; John T. Vetto, Oregon Health & Science University/Knight Cancer Institute, Portland, OR; Frank G. Haluska, Tufts-New England Medical Center, Boston, MA; Alberto S. Pappo, Texas Children's Cancer Center, Houston, TX; Jeffrey A. Sosman, Vanderbilt University School of Medicine Nashville, TN; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.1590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226807PMC
November 2014

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

Front Oncol 2014 29;4:266. Epub 2014 Sep 29.

Department of Dermatology, University of Pittsburgh , Pittsburgh, PA , USA ; Department of Immunology, University of Pittsburgh , Pittsburgh, PA , USA ; University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178427PMC
October 2014

State of melanoma: an historic overview of a field in transition.

Hematol Oncol Clin North Am 2014 Jun;28(3):415-35

Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, 5150 Centre Avenue, Pittsburgh, PA 15232, USA; Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, 5115 Centre Avenue, Suite 1.32, Pittsburgh, PA 15232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.02.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040458PMC
June 2014